Windtree Therapeutics Files 8-K

TL;DR

Windtree Therapeutics filed an 8-K on Oct 6, 2025, reporting a material agreement and financials.

AI Summary

On October 6, 2025, Windtree Therapeutics, Inc. filed an 8-K report to disclose a material definitive agreement and financial statements. The company, previously known as Discovery Laboratories Inc. and Ansan Pharmaceuticals Inc., is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing indicates significant corporate activity or financial reporting by Windtree Therapeutics, which could impact investors' understanding of the company's current status.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports material events or financial updates without immediate, significant new risks.

Key Numbers

• 001-39290 — Commission File Number (SEC identifier for the company)
• 94-3171943 — I.R.S. Employer Identification No. (Company tax identification number)

Key Players & Entities

• Windtree Therapeutics, Inc. (company) — Registrant
• October 6, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Discovery Laboratories Inc. (company) — Former company name
• Ansan Pharmaceuticals Inc. (company) — Former company name
• 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976 (address) — Principal executive address

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock , par value $0.001 per share WINT OTCID Indicate by ch
• $3 million — (the "Notice"). The Notice demanded the $3 million in earnest money (the "Earnest Money")
• $1,400,000 — row agent for the transaction, of which $1,400,000 was paid by the Company with the remain
• $750,000 — instructs the Escrow Holder to release $750,000 of the Earnest Money to WINT and to rel

Filing Documents

• wint20251001_8k.htm (8-K) — 27KB
• ex_866665.htm (EX-10.1) — 40KB
• 0001437749-25-030516.txt ( ) — 201KB
• wint-20251006.xsd (EX-101.SCH) — 3KB
• wint-20251006_def.xml (EX-101.DEF) — 11KB
• wint-20251006_lab.xml (EX-101.LAB) — 14KB
• wint-20251006_pre.xml (EX-101.PRE) — 11KB
• wint20251001_8k_htm.xml (XML) — 3KB

01

Item 1.01 Settlement of a disputed Material Definitive Agreement Settlement of a disputed Purchase Agreement As previously disclosed, on April 19, 2025, WINT Real Estate, LLC ("WINT LLC"), a wholly owned subsidiary of the Company, entered into an Assignment and Conditional Assumption Agreement (the "Assignment") with Way Maker Growth Fund, LLC ("Way Maker") relating to that certain Purchase and Sale Agreement dated June 28, 2024, as amended (the Purchase Agreement), between Way Maker and TBB Crescent Park Drive LLC ("TBB CPD"). Pursuant to the Purchase Agreement, TBB CPD agreed to sell to Way Maker real property commonly known as the Aubrey, located at 11755 Southlake, Houston, Texas. Pursuant to the terms of the Assignment, Way Maker agreed to assign to WINT LLC its right, title and interest in the Purchase Agreement. As disclosed on June 24, 2025, TBB CPD provided a notice of termination with respect to the Purchase Agreement to the Company (the "Notice"). The Notice demanded the $3 million in earnest money (the "Earnest Money") held by the escrow agent for the transaction, of which $1,400,000 was paid by the Company with the remainder by Way Maker, be released to TPP CPD. The Company had disputed TPP CPD's entitlement to the Earnest Money. On September 30, 2025, WINT LLC and TBB entered into a Settlement and Mutual Release Agreement (the "Agreement") which instructs the Escrow Holder to release $750,000 of the Earnest Money to WINT and to release the remaining Earnest Money to TBB. In addition, the parties agree that the Purchase Agreement is validly terminated and WINT has no rights with regard to the Property along with a mutual release of claims as defined in the Agreement.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 10.1 Settlement Agreement and Mutual Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Jed Latkin Name: Jed Latkin Title: President and Chief Executive Officer Date: October 6, 2025

View Full Filing

View this 8-K filing on SEC EDGAR